Biotech Values

[Titan V]

Merck CEO sees Keytruda in pole position in cancer race
http://reut.rs/2iNX86R

Chief Executive Ken Frazier said that Keytruda in combination therapy could also be cheaper than some rival approaches -- an increasingly important consideration in an era of heightened controversy about high drug prices.

The U.S. Food and Drug Administration (FDA) is due to decide by May 10 whether to approve a combination of the immune system-boosting drug with chemotherapy as an initial therapy for advanced lung cancer, the largest cancer market.

The rapid FDA review means that the U.S. drugmaker could leapfrog rivals in the race for combination treatments.